Endocyte, Inc.
NASDAQTotal Valuation
Endocyte, Inc. carries a market capitalization of - -, placing it among publicly traded companies globally. Its enterprise value stands at 820.59M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | - - |
| Enterprise Value | 820.59M |
Share Statistics
Endocyte, Inc. currently has 81.32M shares outstanding.
| Shares Outstanding | 81.32M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 9,052.26, and the price-to-book ratio stands at -3.41.
| PE Ratio | N/A |
| PS Ratio | 9,052.26 |
| PB Ratio | -3.41 |
| P/TBV Ratio | 3.35 |
| P/FCF Ratio | -29.12 |
| P/OCF Ratio | -28.74 |
Enterprise Valuation
| EV / Sales | 6,377.22 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Endocyte, Inc. maintains a current ratio of 45.77, meaning it holds 45.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 45.77 |
| Quick Ratio | 44.86 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -17.89 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Endocyte, Inc.'s stock has gained approximately 0% over the past 52 weeks. The 50-day moving average sits at 23.21, while the 200-day moving average is 16.45.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 23.21 |
| 200-Day Moving Average | 16.45 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Endocyte, Inc. generated 128,675.00 in revenue and converted that into -41.34M in net income, yielding earnings per share of -0.63. EBITDA reached -42.82M, while operating income came in at -43.64M.
| Revenue | 128,675.00 |
| Gross Profit | N/A |
| Operating Income | -43.64M |
| Pretax Income | -41.34M |
| Net Income | -41.34M |
| EBITDA | -42.82M |
| EBIT | -43.64M |
| Earnings Per Share (EPS) | -0.63 |
Balance Sheet
Total book value stands at -341.31M, with working capital of 343.64M providing operational flexibility.
| Cash & Cash Equivalents | 344.21M |
| Total Debt | N/A |
| Net Debt | -67.27M |
| Equity (Book Value) | -341.31M |
| Book Value Per Share | -5.20 |
| Working Capital | 343.64M |
Cash Flow
Endocyte, Inc. produced -40.53M in operating cash flow over the past twelve months. After subtracting -526,932.00 in capital expenditures, free cash flow totaled -41.06M - equivalent to -0.63 per share.
| Operating Cash Flow | -40.53M |
| Capital Expenditures | -526,932.00 |
| Free Cash Flow | -41.06M |
| FCF Per Share | -0.63 |
Margins
Endocyte, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -33,915.81 and net profit margin of -32,126.55 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -33,915.81 |
| Pretax Margin | -32,126.55 |
| Profit Margin | -32,126.55 |
| EBITDA Margin | -33,279.25 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -24.09 |
| FCF Yield | -3.43 |
Scores
Endocyte, Inc. posts an Altman Z-Score of 86.69, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 86.69 |